Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Nursing Diagnosis01:22

Nursing Diagnosis

Following assessment, a nursing diagnosis is the next step in the nursing process. It begins after the nurse has collected and recorded the patient data. The purpose of diagnosing is to identify how the client responds to actual or potential health processes, identify factors that bestow or that cause health problems, the etiologies, and identify resources or strengths the individual, group, or community can draw on to prevent or resolve problems.
The nursing diagnosis focuses on evidence-based...
Methods of Documentation IV: Focus Charting01:26

Methods of Documentation IV: Focus Charting

Focus Charting, also known as the focus charting system or "focus documentation," is a systematic documentation approach used in healthcare to organize patient information in medical records.
It typically involves three columns for recording information:
Methods of Documentation VI: Case Management Model01:15

Methods of Documentation VI: Case Management Model

The case management model is a multidisciplinary approach that involves healthcare professionals from diverse disciplines, such as physicians, nurses, therapists, social workers, and pharmacists, working collaboratively to address the various needs of patients. Each healthcare professional brings unique expertise and perspectives, contributing to a more comprehensive understanding of the patient's condition and tailoring treatment plans accordingly.
For example, a patient with a chronic illness...
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it produces...
Strategies for Assessing and Addressing Confounding01:25

Strategies for Assessing and Addressing Confounding

Confounding is a critical issue in epidemiological studies, often leading to misleading conclusions about associations between exposures and outcomes. It occurs when the relationship between the exposure and the outcome is mixed with the effects of other factors that influence the outcome. Given that, addressing confounding is of high importance for drawing accurate inferences in research.
Confounding can be addressed at both the design phase of a study and through analytical methods after data...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Donanemab treatment effect by baseline tau burden and disease severity: Observations from the TRAILBLAZER-ALZ 2 trial.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Efficacy and safety of donanemab in the European eligible population: TRAILBLAZER-ALZ 2 post-hoc analyses.

The journal of prevention of Alzheimer's disease·2026
Same author

Go-Along Virtual INTERview (GVIv): A Novel Nurse-Led Qualitative Method for Exploring Neighborhood Lived Experience and Health.

Global qualitative nursing research·2026
Same author

Comment on: The impact of psychological trauma on weight loss, psychosocial functioning, and psychopathology in bariatric and metabolic surgery candidates: a systematic review.

Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery·2026
Same author

Clinical Meaningfulness of Donanemab in Early Symptomatic Alzheimer Disease: Data From the Randomized Phase 3 TRAILBLAZER-ALZ 2 Trial.

Neurology. Clinical practice·2026
Same author

Characterizing the Diffusion Properties of Prostate Tissue Using Paired MR Microscopy and Multidimensional Diffusion MRI.

Magnetic resonance in medicine·2026

相关实验视频

Updated: Jul 7, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K

如何donanemab数据解决覆盖范围与证据开发问题.

Eric G Klein1, Krista Schroeder2, Alette M Wessels2

  • 1Global Medical Affairs, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, Indiana, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|February 7, 2024
PubMed
概括

在早期阿尔茨海默病 (AD) 患者中,多纳尼马布显著减缓了认知衰退. 该药物表现出可管理的安全性,支持重新考虑AD治疗的覆盖范围.

关键词:
阿尔茨海默病的疾病阿尔茨海默病的疾病.医疗保险和医疗补助服务中心.覆盖与证据开发的覆盖.美国医疗保险 (Medicare) 的医疗保险.国家覆盖范围的确定与粉样蛋白相关的成像异常.胺胺向治疗的治疗方法抗粉胺单克隆抗体的抗粉胺单克隆抗体.大脑出血 脑出血大脑胀大脑胀认知和功能衰退 认知和功能衰退痴呆症 痴呆症是一种痴呆症.没有的,没有的,没有的.早期症状性阿尔茨海默氏病的早期症状.健康结果的健康结果.轻度的认知障碍 轻度的认知障碍知道的 知道的 知道的

更多相关视频

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

6.8K
Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

3.5K

相关实验视频

Last Updated: Jul 7, 2026

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.8K
Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides
05:16

Characterizing Exon Skipping Efficiency in DMD Patient Samples in Clinical Trials of Antisense Oligonucleotides

Published on: May 7, 2020

6.8K
Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens
13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

3.5K

科学领域:

  • 神经学 神经学
  • 药理学 药理学是指药理学的学科.
  • 临床试验 临床试验

背景情况:

  • 阿尔茨海默病 (AD) 构成了重大挑战,需要有效的治疗方法.
  • 医疗保险和医疗补助服务中心 (CMS) 建立了证据开发 (CED) 标准的覆盖范围,用于针对AD的粉样蛋白向单克隆抗体.
  • 多纳尼马布是一种针对粉样斑块的试验性单克隆抗体.

研究的目的:

  • 评估donanemab在治疗早期症状性阿尔茨海默病 (AD) 的有效性.
  • 评估多纳尼马布在医疗保险受益人群中具有代表性的安全性.
  • 为CMS提供证据,以重新考虑其针对粉样蛋白向疗法的国家覆盖率确定 (NCD).

主要方法:

  • 对donanemab的TRAILBLAZER-ALZ注册试验数据的分析.
  • 包含支持文献和现实世界的数据来解决CED问题.
  • 评估早期症状AD参与者的认知,功能和安全结果.

主要成果:

  • 多纳尼马布显著减缓了粉胺阳性早期症状AD参与者的认知和功能衰退.
  • 在接受了donanemab治疗的参与者中,疾病进展的风险降低了.
  • 关键的安全风险,主要是粉样蛋白相关的成像异常,发生在前6个月内,随后随着监测而下降.

结论:

  • 多纳内马布在早期症状性阿尔茨海默病的健康结果中显示出有意义的改善,具有可管理的安全性.
  • 试验参与者的人口统计,并发症和并发药物与更广泛的医疗保险人口保持一致.
  • 提出的证据支持重新考虑目前的国家覆盖率确定 (NCD) 的donanemab.